A National, Multi Center, Randomized, Open-label, Phase II Trial of Erlotinib Versus Combination of GC as (Neo)Adjuvant Treatment in Stage IIIA-N2 NSCLC With Sensitizing EGFR Mutation in Exon 19 or 21(EMERGING)

Trial Profile

A National, Multi Center, Randomized, Open-label, Phase II Trial of Erlotinib Versus Combination of GC as (Neo)Adjuvant Treatment in Stage IIIA-N2 NSCLC With Sensitizing EGFR Mutation in Exon 19 or 21(EMERGING)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms EMERGING; TARGET
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Feb 2017 Planned End Date changed from 1 Mar 2016 to 1 Mar 2018.
    • 28 Feb 2017 Planned End Date changed from 1 Mar 2016 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top